4.7 Article

Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide

Journal

INTERNATIONAL JOURNAL OF CANCER
Volume 116, Issue 2, Pages 187-192

Publisher

WILEY
DOI: 10.1002/ijc.21071

Keywords

glioma; p53; pifithrin-alpha; BCNU; TMZ; chemotherapy; cell cycle; DNA repair

Categories

Ask authors/readers for more resources

Pifithrin-alpha (PFT alpha) is a small molecule inhibitor of p53. By reversibly blocking apoptosis in response to DNA damage, PFT alpha protects normal cells from lethal doses of gamma-radiation (Komarov et al., Science, 1999;285:1733-7). We examined the effect of PFT alpha on the chemosensitivity of a human cancer in which cell cycle arrest, not apoptosis, is the principle cellular consequence of p53 activation. This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas. We observed that exposure of U87MG cells to PFT alpha before cytotoxic chemotherapy attenuated p53-mediated induction of p21WAF1 protein levels, sensitizing U87MG cells to BCNU and TMZ. Sensitization of U87MG cells was associated with G1 arrest, delayed entry into S-phase and decreased repair of DNA damage by BCNU. Our findings suggest that in addition to protecting normal cells from the toxic effects of radiation and chemotherapy, small molecule inhibitors of p53, like PFT alpha, might play a role in clinical oncology by sensitizing certain resistant cancers to cytotoxic chemotherapies. (c) 2005 Wiley-Liss, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available